Pretax income is the income that a company earns before paying income taxes. Kymera Therapeutics's pretax income for the
three
months ended in Dec. 2024 was $-70.75 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-223.86 Mil.
Kymera Therapeutics's pretax margin was -956.88%.
During the past 7 years, Kymera Therapeutics's highest Pretax Margin was -133.96%. The lowest was -1405.79%. And the median was -258.80%.
Kymera Therapeutics Pre-Tax Income Historical Data
The historical data trend for Kymera Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kymera Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Kymera Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kymera Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kymera Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Kymera Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-223.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics (NAS:KYMR) Pre-Tax Income Explanation
Kymera Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 7 years, Kymera Therapeutics's highest Pretax Margin was -133.96%. The lowest was -1405.79%. And the median was -258.80%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Kymera Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KYMR has been successfully added to your 